Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 7/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968519 | 1.00 | KDM4E (0.58) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL20361090 | 0.86 | KDM4E (0.60) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL14661429 | 0.84 | RAB9A (0.44) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL13798438 | 0.81 | CNR1 (0.46) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL30968436 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL20722895 | 0.81 | ALDH1A1 (0.44) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL29730728 | 0.80 | KDM4E (0.63) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL259266 | 0.80 | KDM4E (0.63) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL16375108 | 0.77 | KDM4E (0.61) | KDM4EALDH1A1MAPTRAB9ANPC1 | |
| SCHEMBL30916867 | 0.77 | KDM4E (0.76) | KDM4EALDH1A1MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| EP-2467387-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS. | KARUS THERAPEUTICS LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| EP-2467387-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | Karus Therapeutics Limited (GB) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021038-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LIMITED (GB) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | KDM4E 403/4885ALDH1A1 2167/4885MAPT 2661/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | KDM4E 403/4885ALDH1A1 2167/4885MAPT 2661/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | KDM4E 403/4885ALDH1A1 2167/4885MAPT 2661/4885 |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | PIK3CA, PIK3CD, PIK3C2A | KDM4E 2630/4885ALDH1A1 4398/4885MAPT 4833/4885 |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3R2, PIK3R1, PIK3CA | KDM4E 2217/4885ALDH1A1 3613/4885MAPT 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.